Insight Molecular Diagnostics Inc. (IMDX)

Market Cap	71.55M
Revenue (ttm)	4.26M
Net Income (ttm)	-63.42M
Shares Out	28.62M
EPS (ttm)	-2.85
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	64,375
Open	2.640
Previous Close	2.600
Day's Range	2.400 - 2.640
52-Week Range	1.922 - 4.750
Beta	1.05
Analysts	Strong Buy
Price Target	4.25 (+70.0%)
Earnings Date	Aug 11, 2025

About IMDX

Insight Molecular Diagnostics Inc. operates as a precision diagnostics company in the United States and internationally. The company develops and commercializes laboratory developed tests, kitted research use only tests, and kitted clinical tests. It is developing DetermaCNI, a blood-based monitoring tool that detects progression early after one cycle cancer treatment; and DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies. The company also offers VitaGraft Kidney, a blood-based tra...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 2009
• Employees: 49
• Stock Exchange: NASDAQ
• Ticker Symbol: IMDX
• Website: https://imdxinc.com

Financial Performance

In 2024, IMDX's revenue was $1.88 million, an increase of 25.15% compared to the previous year's $1.50 million. Losses were -$60.93 million, 112.1% more than in 2023.

Analyst Summary

According to one analyst, the rating for IMDX stock is "Strong Buy" and the 12-month stock price target is $4.25.

Price Target

$4.25

(70.00% upside)

Analyst Consensus: Strong Buy